Effect of Preemptive Etoricoxib and Dexamethasone on Wound Healing and Clinical Parameters After Third Molar Surgery
Status:
Completed
Trial end date:
2022-12-26
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to compare preemptive single-dose selective cyclooxygenase
2 (COX-2) inhibitor - etoricoxib and dexamethasone use in systemically healthy patients
during the surgical extraction of impacted mandibular third molars. The main questions it
aims to answer/evaluate are:
- the level of inflammatory and early wound healing mediators in patients' saliva during
early postoperative phase
- clinical postoperative parameters such as pain, swelling and trismus
- patient satisfaction with the treatment
- rescue medication consumed during the postoperative period
- incidence of adverse events
Participants indicated for mandibular third molar surgery will be asked to:
- take premedication (etoricoxib or dexamethasone) before surgical extraction
- provide saliva samples before and following the surgery at regular check-ups
- note the amount of rescue medication taken and pain intensity in different time points
- perform clinical measurements of swelling and trismus at regular check-up visits
- answer the questions about satisfaction and potential adverse events, if occur
Researchers will compare preemptive single-dose etoricoxib, preemptive single-dose
dexamethasone, and no premedication in impacted mandibular third molar surgery, to see
if there are differences in inflammatory response and early wound healing, as well as in
clinical postoperative parameters, patient satisfaction with the treatment and incidence
of potential adverse events.